CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma.
A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
工程化树突状细胞（DCs）用于治疗癌症是细胞免疫疗法长期追求的目标。在本综述中，我们聚焦于CMN-001（原称AGS-003）的经验，这是一种基于DC的免疫疗法，采用自体DC电穿孔导入自体肿瘤RNA来治疗转移性肾细胞癌（mRCC）受试者。我们将回顾CMN-001的早期临床开发，直至包括在多中心3期研究中的部署，并提供继续在正在进行的随机2期研究中开发CMN-001的理由。在3期研究中观察到的CMN-001与依维莫司之间的协同作用，为设计一项2b期研究提供了机会，该研究基于CMN-001的作用机制以及早期研究中揭示的潜在免疫和临床结局。2b期研究的设计将CMN-001与一线检查点抑制疗法以及二线仑伐替尼/依维莫司联合用于poor-risk mRCC受试者。
Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS-003, a DC-based immunotherapy, employing autologous DC electroporated with autologous tumor RNA to treat subjects with metastatic renal cell carcinoma (mRCC).
We will review the early clinical development of CMN-001 up to and including deployment in a multicenter phase 3 study and provide a rationale to continue the development of CMN-001 in an ongoing randomized phase 2 study.
The synergy between CMN-001 and everolimus observed in the phase 3 study provides an opportunity to design a phase 2b study building on the mechanism of action of CMN-001 and underlying immune and clinical outcomes revealed in the earlier studies. The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
